The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.00
Bid: 47.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.255%)
Open: 48.00
High: 48.00
Low: 48.00
Prev. Close: 48.00
MIG3 Live PriceLast checked at -
Maven Income and Growth VCT 3 is an Investment Trust

To achieve long-term capital appreciation and generate income for Shareholders by investing in a diversified portfolio of securities in smaller, unquoted UK companies and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re Offer for Subscription

14 Nov 2019 18:20

RNS Number : 4971T
Maven Income and Growth VCT 3 PLC
14 November 2019
 

Maven Income and Growth VCT 3 PLC

Maven Income and Growth VCT 4 PLC

 

14 November 2019

 

Offer for Subscription

 

The board of directors of Maven Income and Growth VCT 3 PLC ("Maven VCT 3") and Maven Income and Growth VCT 4 PLC ("Maven VCT 4") (together the "Companies" and each a "Company") are pleased to announce that they have published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription for new Ordinary Shares of 10p each in the Companies to raise, in aggregate, up to £15 million (before issue costs) (the "Offers").

 

Each of the Companies has also published a circular (a "Circular") seeking the approval from their respective shareholders for matters in connection with the Offers, each Company giving notice of a general meeting of that company to be held on 10 December 2019 (each a "General Meeting").

 

The Offers are now open and are expected to close no later than 1 April 2020 in relation to the tax year 2019/20 and on 30 April 2020 in relation to the tax year 2020/21 (unless the relevant Offer is fully subscribed by an earlier date or previously extended by the relevant board to no later than 3 November 2020).

 

Each Offer is conditional on the passing of the requisite resolutions at the relevant General Meeting.

 

At its General Meeting, Maven VCT 4 will also be seeking shareholder approval of the proposals for Maven VCT 4 to merge with Maven Income and Growth VCT 6 PLC (to be effected pursuant to a scheme of reconstruction under section 110 of the Insolvency Act 1986) (the "Merger").

 

Pursuant to individual offer agreements dated 13 November 2019 relating to each Offer between, among others, each relevant Company and Maven Capital Partners LLP ("Maven"), Maven, as the administrator of the Offer, will receive an offer administration fee of 2.5% of the application amount in relation to each accepted application, with reductions to the fee applying in certain cases (for instance, early applications under the Offers). Maven as the investment manager of each Company is a related party of each Company under the Listing Rules, and the payment of such a fee by the Company to Maven is a transaction to which Listing Rule 11.1.10R applies.

 

Further, William Nixon has expressed his intention, prior to the close of each of the Offers, to subscribe £50,000 in Maven VCT 3 and £50,000 in Maven VCT 4 under the relevant Offer. As a director of each of the Companies, William Nixon is a related party of the relevant Company under the Listing Rules and, consequently, each subscription is a transaction to which Listing Rule 11.1.10R applies.

 

To obtain a copy of the Securities Note, private investors and financial advisers should call Maven Capital Partners LLP on 0141 306 7400. A downloadable version of the Securities Note will also be available from www.mavencp.com/vctoffer, or from each of the Company's websites: www.mavencp.com/migvct3 and www.mavencp.com/migvct4.

 

Copies of the Prospectus and the Circulars are available, free of charge, from Maven Capital Partners UK LLP at Kintyre House, 205 West George Street, Glasgow G2 2LW.

 

In accordance with the Listing Rules, the Prospectus and Circular have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

 

Any enquiries in respect of the Offers or the Merger should be directed to:

Maven Capital Partners UK LLP

Telephone: 0141 306 7400E-mail: enquiries@mavencp.com 

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRLLFITLALSLIA
Date   Source Headline
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:37 pmRNSIssue of Equity
28th Mar 202410:16 amRNSStatement re Offer for Subscription
27th Mar 202410:36 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:46 pmRNSUnaudited Net Asset Value
15th Mar 20245:18 pmRNSAnnual Financial Report
21st Feb 20244:24 pmRNSTransaction in Own Shares
8th Feb 202410:30 amRNSDirector/PDMR Shareholding
8th Feb 202410:28 amRNSDirector/PDMR Shareholding
8th Feb 202410:15 amRNSIssue of Equity
6th Feb 202411:07 amRNSDividend Declaration
19th Dec 20233:25 pmRNSIssue of Equity
18th Dec 20235:17 pmRNSUnaudited Net Asset Value
5th Dec 202311:42 amRNSDirectorate Change
9th Nov 20233:47 pmRNSResult of General Meeting
8th Nov 20234:01 pmRNSTransaction in Own Shares
7th Nov 20234:47 pmRNSTransaction in Own Shares
19th Oct 20234:15 pmRNSNet Asset Value
13th Oct 20234:56 pmRNSPublication of a Prospectus
25th Aug 20239:38 amRNSIssue of Equity
21st Aug 20233:28 pmRNSStatement re Dividend Investment Scheme
21st Jul 202312:52 pmRNSHalf-year Report
13th Jul 20234:04 pmRNSTransaction in Own Shares
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
30th Jun 20234:22 pmRNSNet Asset Value and Interim Dividend
2nd Jun 20239:41 amRNSIssue of Equity
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
24th Apr 202312:51 pmRNSResult of AGM
19th Apr 20234:49 pmRNSTransaction in Own Shares
19th Apr 20231:05 pmRNSNet Asset Value - Dividend Investment Scheme
5th Apr 202312:29 pmRNSIssue of Equity
4th Apr 202311:43 amRNSNet Asset Value(s)
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
14th Mar 20234:31 pmRNSAnnual Financial Report
3rd Mar 20239:53 amRNSIssue of Equity
21st Feb 20234:41 pmRNSTransaction in Own Shares
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202311:06 amRNSDirector/PDMR Shareholding - Replacement
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:08 amRNSDirector/PDMR Shareholding
8th Feb 20239:43 amRNSIssue of Equity
1st Feb 20233:23 pmRNSUnaudited NAV and Proposed Final Dividend
12th Dec 20223:41 pmRNSDirectorate Change
12th Dec 20223:34 pmRNSStatement re Director's Other Quoted Directorships
9th Nov 20223:00 pmRNSResult of General Meeting
4th Nov 20222:35 pmRNSTransaction in Own Shares
31st Oct 20223:54 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.